TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07282665: A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER

Sponsor: Pfizer · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 32500 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07282665 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07282665 Rescue Dossier →